NCT05539300View on ClinicalTrials.gov

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

PSMA-PET/CT response evaluation

PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy

Trial Locations (1)

3583VS

RECRUITING

Roderick van den Bergh, Utrecht

All Listed Sponsors
lead

UMC Utrecht

OTHER